Neurocrine Biosciences, Inc. announced the presentation of new analyses from a Phase 4 randomized withdrawal study, demonstrating significant patient-reported improvements in health-related quality of life and functional measures among adults aged 65 years and older with tardive dyskinesia (TD) who received continued treatment with INGREZZA capsules. These findings will be presented at the 2025 American Association of Nurse Practitioners National Conference.
These post-hoc analyses of older adults expand on recently announced Phase 4 study results, which demonstrated that continued treatment with INGREZZA improved functional status and quality of life measures across the general patient population. Patients who received continued treatment with INGREZZA reported significant improvements in health-related quality of life and functional status, compared with those randomized to placebo.
Older adults are at increased risk for developing TD and are more susceptible to the profound physical, functional, and social consequences of uncontrolled movements. These new data demonstrate that INGREZZA can provide significant and persistent improvements in quality of life for older adults with TD, consistent with the substantial body of evidence for INGREZZA treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.